quantisnow
FeedTopReportsPricing
⌘K
Live feed
07:00:00·1976d
PRRelease
Sutro Biopharma Inc. logo
Celgene Corporation logo

Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer

STRO· Sutro Biopharma Inc.CELG~· Celgene Corporation
Health Care
Original source

Companies

  • STRO
    Sutro Biopharma Inc.
    Health Care
  • CELG~
    Celgene Corporation
    n/a

Recent analyst ratings

  • Apr 7STROUpdateLeerink Partners$38.00
  • Mar 24STROUpdateWells Fargo$27.00
  • Mar 24STROUpdateH.C. Wainwright$28.00
  • Jan 20STROUpdateCitizens JMP$23.00
  • Jun 16STROUpdatePiper Sandler$2.00
  • Mar 17STROUpdateH.C. Wainwright-

Related

  • SEC1d
    SEC Form DEFA14A filed by Sutro Biopharma Inc.
  • SEC1d
    SEC Form DEF 14A filed by Sutro Biopharma Inc.
  • SEC2d
    Amendment: SEC Form SCHEDULE 13G/A filed by Sutro Biopharma Inc.
  • SEC2d
    SEC Form SCHEDULE 13G filed by Sutro Biopharma Inc.
  • PR4d
    Sutro Biopharma Presents Promising Preclinical Data Across its Pipeline of Next-Generation Single and Dual-Payload ADC Programs at AACR 2026
  • ANALYST16d
    Leerink Partners initiated coverage on Sutro Biopharma with a new price target
  • SEC22d
    SEC Form EFFECT filed by Sutro Biopharma Inc.
  • SEC22d
    SEC Form 424B3 filed by Sutro Biopharma Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022